Cocarboxylase, ampoules 50mg, 5pcs

Composition

1 ampoule (bottle )with powder for preparing a solution for injection contains:

Active ingredient:

cocarboxylase hydrochloride 50 mg

Pharmacological action

Cocarboxylase is a coenzyme of thiamine (vitamin B1), phosphorylated in the body to form mono -, di-and triphosphoric esters, and is a part of enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids.

To participate in these processes, exogenous vitamin B1 (thiamine) must be metabolized by phosphorylation to cocarboxylase, a ready — made form of the coenzyme.

It should be noted that the properties of cocarboxylase are only partially adequate to those of thiamine; cocarboxylase is not used for the prevention and treatment of hypo-and beriberi in 1.

Indications

• Metabolic acidosis,
• hyperglycemic coma and acidosis in diabetes,
• hepatic and renal failure,
• respiratory acidosis in chronic, cardiopulmonary failure,
• respiratory failure,
• chronic heart failure,
• ischemic heart disease,
• myocardial infarction and post-infarction cardiosclerosis (in the complex therapy), acute alcohol poisoning and chronic alcoholism;
• the poisoning of digitalis drugs, barbiturates,
• intoxication in infectious diseases: diphtheria, scarlet fever, typhoid and paratyphoid (in the complex therapy), peripheral neuritis.

Use during pregnancy and lactation

There are no data on the safety of the drug when it is used in pregnant women.

Due to the insufficient number of studies, the drug should not be prescribed to pregnant and lactating women.

Contraindications

Hypersensitivity to the drug.

Side effects

Allergic reactions (urticaria, pruritus) are possible; with intramuscular use — hyperemia, pruritus, edema (at the injection site).

Interaction

Cocarboxylase enhances the effect of cardiac glycosides and improves their tolerance.

How to take, course of use and dosage

Cocarboxylase is administered intramuscularly.

The dose is set individually, depending on the nature of the disease and the severity of the patient’s condition.

Adults: 50-100 mg / day, once, if necessary (diabetic coma) – again in 1-2 hours; in the future, switch to a maintenance dose of 50 mg/day; in case of circulatory insufficiency,50 mg is administered 2 hours before the use of digitalis preparations 2-3 times a day.

Children per day (in 1-2 doses): up to 3 months-25 mg, from 4 months to 7 years-25-50 mg, from 8 to 18 years-50-100 mg

Overdose

If the dose prescribed by the doctor is exceeded, symptoms of overdose may occur in the form of: tachycardia; nausea; vomiting; headache; weakness; fatigue; muscle spasms; impaired activity of the cardiovascular system; allergic reactions; increased sweating; shortness of breath.

If symptoms of overdose occur, the drug is canceled and mandatory symptomatic treatment is performed.

Special instructions

Due to the presence of glycocholic acid as an auxiliary substance, with repeated and prolonged use of the drug in patients with jaundice or severe cholestasis (changes in the indicators of laboratory liver function tests), it is necessary to carefully monitor liver function.

Deficiency of one or more vitamins should be corrected by use of the missing vitamin preparation. Cernevit does not contain vitamin K, which can be administered separately if necessary.

After dilution, the drug is stable at a temperature of no more than 25°C for 24 hours, but the drug is recommended to be used immediately after dilution or stored for no more than 24 hours at a temperature of 2° to 8°C.

Influence on the ability to drive motor vehicles and manage mechanisms

Since Cernevit is intended for patients receiving parenteral nutrition and who are in severe and moderate condition, the ability to drive a car and work with mechanisms was not evaluated.

Form of production

Lyophilizate for solution preparation for intramuscular injection

Storage conditions

In a dark place, at a temperature not exceeding 20 °C

Shelf life

3 years

Active ingredient

Cocarboxylase

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Indications

Angina pectoris, Chronic circulatory failure, Prevention of acute myocardial infarction, Coronary heart disease